Loading stock…

Johnson & Johnson (JNJ) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Johnson & Johnson

JNJMarket cap $618BPrice $256.5

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Makes medicines, medical devices, and consumer products from Band-Aids to cancer treatments. This 138-year-old giant touches more lives daily than almost any company on Earth through its ubiquitous healthcare products.

In Bastion Portfolios?

52W Return+34%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+8%6

Rev CAGR (5y)+8%7

Earnings Forecast

EPS Growth Y+1+2%4

EPS Growth Y+2+8%6

EPS Growth Y+3+23%8

Quality

Margins

EBIT Margin28%9

Net Income Margin21%8

Free Cash Flow Margin23%8

Debt

Net Debt/EBITDA0.86

Efficiency

ROE26%9

ROA11%9

Earnings Stability44

GEAR+VERY STRONG91

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)223

P/E Ratio (Forward 3y)174

P/BV7.32

EV Multiples

EV/EBITDA Fwd183

EV/EBIT Fwd204

Yield

Free Cash Flow Yield3.6%5

Dividend Yield2.1%5

Momentum

Short term

1 month return-4%5

3 month return-1%6

YTD return+26%8

Mid term

Price vs 52wHigh91%9

1 year return+37%8

Long term

3 year return+76%7

5 year return+83%7

Risk Shield

Price Risk

Beta-0.010

Volatility19%10

Free Cash Flow

Free Cash Flow Margin23%8

Free Cash Flow Yield3.6%5

Quality

ROCE19%8

Earnings Stability44

Net Debt/EBITDA0.86

02Growth

Is it actually growing, and how fast?

JNJJohnson & Johnson

Revenue FY25$94.2B

GROWTH RATING↗

AVERAGE56 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+2%4

EPS growth, FY27E+8%6

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 56% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG76 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-1%6

YTD return+26%8

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return+37%8

3-year return+76%7

5-year return+83%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +76% over three years and +83% over five, ahead of 60% of the market.

It's up 37% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+26%).

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns and the stock sits near its highs. A reliable trend, if not the single hottest name in the market.

04Value

Are you paying a fair price for it?

Stop guessing on J&J. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

JNJJohnson & Johnson

Revenue FY25$94.2B

GROWTH RATING↗

AVERAGE56 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+2%4

EPS growth, FY27E+8%6

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 56% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG76 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-1%6

YTD return+26%8

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return+37%8

3-year return+76%7

5-year return+83%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +76% over three years and +83% over five, ahead of 60% of the market.

It's up 37% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+26%).

WATCH

Returns sit at the market level over the past month (-4%) and over three months (-1%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns and the stock sits near its highs. A reliable trend, if not the single hottest name in the market.

04Value

Are you paying a fair price for it?

Stop guessing on J&J. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community